Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.40 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | BMP1 | P13497 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97580 | 0.86 | GLO1 (0.40) | FOLH1RIMKLANAALAD2CCKBRBMP1 | |
| SCHEMBL27265533 | 0.79 | PRMT1 (0.45) | EPHX2 | |
| SCHEMBL173098 | 0.79 | FOLH1 (0.40) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL27571433 | 0.78 | PTGS1 (0.51) | FOLH1RIMKLANAALAD2BMP1 | |
| SCHEMBL27265592 | 0.78 | SIRT6 (0.45) | FOLH1EPHX2 | |
| SCHEMBL27571430 | 0.78 | PTGS1 (0.51) | FOLH1RIMKLANAALAD2BMP1 | |
| SCHEMBL9800723 | 0.78 | FOLH1 (0.49) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL9800724 | 0.78 | FOLH1 (0.49) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL27265483 | 0.77 | PRMT1 (0.49) | EPHX2 | |
| SCHEMBL22648340 | 0.77 | BMP1 (0.39) | FOLH1RIMKLANAALAD2SIRT5BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058932-A1 | ACTIVE INGREDIENT-PEPTIDE CONSTRUCT FOR EXTRACELLULAR CONCENTRATION | MAX PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-03-08 | — | — | US | disclosed |
| US-20120058932-A1 | ACTIVE INGREDIENT-PEPTIDE CONSTRUCT FOR EXTRACELLULAR CONCENTRATION | MAX PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058932-A1 | ACTIVE INGREDIENT-PEPTIDE CONSTRUCT FOR EXTRACELLULAR CONCENTRATION | VIP, FIBP, MMP7 | FOLH1 198/4885RIMKLA 2508/4885NAALAD2 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.